Non-Hodgkin Lymphoma Journal Articles

• Real World Experience With Camrelizumab in Advanced NSCLC A new study examines the effectiveness and safety of camrelizumab for advanced NSCLC in real-world clinical practice.
  Translational Lung Cancer Research, June 05, 2023
• Strategies to Overcome Resistance to ALK Inhibitors in NSCLC Certain patients with ALK-positive lung cancer may experience drug resistance to ALK-targeted therapy. What are the options?
  Translational Lung Cancer Research, May 22, 2023
• Headache and Systemic Lupus Erythematosus Headache occurs frequently in patients with systemic lupus erythematosus. This review describes the epidemiology, differential diagnosis, and management of headaches in patients with SLE.
  Headache, May 09, 2023
• EHI to Identify Possible COVID-19 Sequelae In what ways could electronic health information be utilized to monitor and identify sequelae of COVID-19?
  Emerging Infectious Diseases, May 09, 2023
• Risks of Second Non-Breast Primaries Following Breast Cancer A better understanding of the potential risks of developing second primary malignancies among survivors of breast cancer could lead to better prevention and management strategies for these patients.
  Breast Cancer Research, May 05, 2023
• Optimal First-Line Treatment for Metastatic ALK+ NSCLC When it comes to first-line treatment options for metastatic ALK+ non-small cell lung cancer, what is the optimal choice?
  Translational Lung Cancer Research, April 20, 2023
• Pulmonary Lymphoma Presenting As a Cavitary Mass in COVID-19 This case highlights the challenges of safely and expeditiously diagnosing and treating aggressive cancers of the respiratory tract in patients acutely infected with SARS-CoV-2.
  Journal of Medical Case Reports, April 07, 2023
• Premature Aging in Young Adult Survivors of Pediatric Cancer A new study assesses premature aging among pediatric cancer survivors as determined by a deficit accumulation index. Could this approach help identify those most at risk of age-related impairments?
  Journal of the National Cancer Institute, March 16, 2023
• Camrelizumab in Inoperable or Advanced NSCLC Patients A new study provides insight into the safety and effectiveness of camrelizumab in real world NSCLC patients with inoperable or advanced disease.
  Translational Lung Cancer Research, March 10, 2023
• Malignant Complications of Celiac Disease What malignancies should one be on alert for in patients with celiac disease?
  Journal of Medical Case Reports, March 10, 2023
• Radiological Case: Brain Abscess This case highlights the presentation, differential diagnosis, and management of brain abscess in an adolescent patient.
  Applied Radiology, February 24, 2023
• Improving the Laboratory Evaluation of Monoclonal Gammopathies The authors developed a targeted clinical decision support alert to address oversights in ordering practices for the initial laboratory evaluation of monoclonal gammopathies.
  American Journal of Clinical Pathology, February 21, 2023
• Effect of Targeted RA Therapies on Inflammation and Anemia In what ways do various targeted DMARDs impact systemic inflammation and anemia in patients with rheumatoid arthritis?
  Arthritis Research & Therapy, February 14, 2023
• Outcomes After ART in Women With Cancer Does a history of cancer impact outcomes of assisted reproductive technology?
  Human Reproduction, February 09, 2023
• There Is No Diagnosis of Exclusion in Rheumatology Learn what is meant by the phrase 'diagnosis of exclusion', and find out why this concept should have no place in rheumatology.
  Rheumatology, February 07, 2023
• Tools for Contralateral Prophylactic Mastectomy Decisions More women are opting to undergo this procedure to help reduce the risk of developing contralateral breast cancer. What tools are available to help them make an informed decision?
  Journal of Clinical Oncology, January 25, 2023
• Extracorporeal Photopheresis and Its Use in Dermatology While cutaneous T-cell lymphoma remains the only FDA approved use of extracorporeal photopheresis, it has potential as an off-label treatment for numerous dermatological conditions.
  Skin Therapy Letter, January 18, 2023
• Filgotinib, Lanraplenib and Tirabrutinib in Sjogren Syndrome Could these drugs prove to be a safe and effective option for the treatment of Sjogren's syndrome?
  Rheumatology, January 03, 2023
• ICIs With Chemotherapy or Anti-Angiogenics for NSCLC Is immune checkpoint inhibitor combination therapy a safe and effective second-line treatment option for advanced non-small cell lung cancer patients?
  Translational Lung Cancer Research, December 07, 2022
• Listening to the Patient Voice Adds Value to Cancer Trials This commentary discusses the value of considering patient-reported outcomes in clinical trials.
  Journal of the National Cancer Institute, December 07, 2022